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Abstract Topical hemostatic agents are used intra-opera-
tively to prevent uncontrolled bleeding. Gelfoam Powder
contains a hemostatic agent prepared from purified pork
skin gelatin, the efficacy of which is increased when
combined with thrombin. However, the effect of increasing
concentrations of thrombin on resultant hemostasis is not
known. This study sought to evaluate the ability of various
concentrations of thrombin in combination with Gelfoam
Powder to control bleeding using a swine liver lesion
model. Ten pigs underwent a midline laparotomy. Circular
lesions were created in the left medial, right medial, and
left lateral lobes; six lesions per lobe. Gelfoam Powder was
hydrated with Thrombin–JMI diluted to 250, 375, and
770 IU/mL. Each concentration was applied to two lesion
sites per lobe. Bleeding scores were measured at 3, 6, 9,
and 12 min using a 6-point system; comparison of bleeding
scores was performed using ANOVA with the post hoc
Tukey test. The bleeding scores with thrombin concentra-
tions at 770 IU/mL were significantly lower than at 250
and 375 IU/mL at all four time points. The percentage of
biopsies with a clinically acceptable bleeding score rose
from 37.9, 46.6, and 71.2 % at 3 min to 55.2, 69.0, and
88.1 % at 12 min in the 250, 375, and 770 IU/mL thrombin
groups, respectively. The study showed that the hemostatic
response to thrombin was dose-related: using higher con-
centrations of thrombin with Gelfoam Powder yielded
improved hemostasis, as determined by lower bleeding
scores.
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Introduction
Maintenance of hemostasis represents a challenge in all
surgical procedures. Although a degree of bleeding is
commonplace during any surgery, untreated or uncon-
trolled bleeding can lead to hematoma, infection, repeat
surgery, blood transfusion, tissue/organ damage, secondary
morbidities, and mortality [1].
Several mechanisms are used to overcome bleeding
during surgery, including direct pressure or pressure
dressing, electrocautery, sutures, and ligatures. In addition,
topical hemostatic agents are highly useful intra-operative
interventions; these can be divided into three groups: (1)
hemostats, which clot blood, e.g., thrombin; (2) sealants,
which prevent leakage, e.g., fibrin sealant; and (3) adhe-
sives, which stick tissues together [2].
Thrombin is a coagulation protein that is available as an
active biological hemostatic agent from bovine, human, or
recombinant (human) sources. Thrombin activates platelets
and converts soluble fibrinogen into insoluble fibrin, thus
providing a lattice for platelet aggregation and thrombus
formation [3]. Application methods can vary: thrombin can
be used in combination with fibrinogen, as a glue to create
a seal [4]; delivered as a spray [5]; or applied in combi-
nation with a gelatin matrix [6]. Multiple surgical
& Dennis C. Morse
Dennis.Morse@pfizer.com
1 Drug Safety Research and Development, Pfizer, 445 Eastern
Point Road, Groton, CT 06355, USA
2 Pfizer, 235 E 42nd Street, New York, NY 10017, USA
3 NAMSA, 6750 Wales Road, Northwood, OH 43619, USA
4 NAMSA, 4050 Olson Memorial Highway, Suite 450,
Minneapolis, MN 55422, USA
5 921 Toledo Ave N, Golden Valley, MN 55422, USA
123
J Thromb Thrombolysis (2016) 42:352–359
DOI 10.1007/s11239-016-1388-6
specialists, including cardiac [7], liver [8], spinal [9], and
vascular surgeons [10], use thrombin alone or in combi-
nation with gelatin products to help control bleeding.
Gelfoam (Pfizer, New York, NY, USA), is a hemo-
static agent prepared from purified pork skin gelatin [11]. It
can be used in its dry form, or it can be saturated with
saline or thrombin prior to use. It is known that the efficacy
of Gelfoam to control bleeding is enhanced when used in
combination with thrombin [12]. However, the effect of
increasing thrombin concentrations when used with Gel-
foam Powder on resultant hemostasis has not previously
been investigated.
In the current study, Gelfoam Powder was prepared with
various concentrations of a topical bovine thrombin,
Thrombin-JMI (Pfizer, New York, NY, USA). The aim of
the study was to evaluate the ability of increasing con-
centrations of thrombin in combination with Gelfoam to
control bleeding in the swine liver lesion model, using a
qualitative 6-point scoring system [12].
Methods
Study species and definitions
The study was conducted by NAMSA, Northwood, OH,
USA, in accordance with FDA Good Laboratory Practice
Regulations, 21 CFR 58. All procedures were performed
under approval from the NAMSA Animal Care and Use
Committee.
The study species, the pig, Sus scrofa domesticus, was
chosen because: (1) the anatomy and physiology of pigs is
considered to be more similar to humans than any other
laboratory animal; (2) pigs provide a better model for
evaluation of bleeding than any other species; and (3) a
large animal model is necessary to provide a large enough
liver surface area for the number of test sites required. For
the purpose of this study, bleeding scores were measured
by a visual, qualitative 6-point scale that has previously
been used in other studies [1, 12–14] (Fig. 1), whereby the
lower the score, the better the indication of hemostasis
outcome. Assessments were made by investigators who
were blinded to the concentration of product used in each
lesion or test article, to maintain objectivity of study
findings.
Animals were observed daily for signs of illness, injury,
or death and any signs of pain including anorexia, reduced
fecal output, vocalization, decreased social interactions,
refusal to move, hunched body position, and limping.
Additionally general appearance, respiratory system, gas-
trointestinal system, neurologic system, and muscu-
loskeletal system were also examined. Body weights were
recorded on day -1. Any animal that was not considered
healthy, based on clinical assessment and body weight, was
not selected for use in the study. Data were collected for
ten female pigs (Yorkshire cross) aged 16–20 months, each
weighing between 70 and 86 kg at surgery. Each animal
had six circular lesions made on each of the left medial,
right medial, and left lateral lobes of the liver.
The test article was Gelfoam Powder composed of
porcine gelatin (Pfizer; Identification SWO 3027 A), pre-
pared with the addition of Thrombin-JMI (Pfizer; Lot
618952) of three different concentrations. Gelfoam Powder
in the amount of 0.550 g was preloaded in a 10 mL syringe
and sterilized by gamma irradiation rather than heat ster-
ilization used for the commercially-available Gelfoam
Powder [15]. Thrombin-JMI (20 K IU) was diluted to
1000 IU/mL with a volume of 20 mL of sodium chloride
USP solution (SC; Pfizer; Lot 648045, 14-017-T03,
3001016). The Gelfoam Powder was then mixed with three
different volumes of the 1000 IU/mL thrombin solution to
yield final concentrations of 250 IU/mL (T250), 375 IU/
mL (T375), and 770 IU/mL (T770). Only technical per-
sonnel preparing the test articles were privy to the thrombin
concentrations. Each of the three test article concentrations
(T250, T375, or T770) was applied to two liver lesion sites
(per lobe). The aim of the study was to evaluate the ability
of increasing concentrations of thrombin in combination
with Gelfoam to control bleeding in the swine liver lesion
model described, using a qualitative 6-point scoring
system.
Coagulation status
Before the liver lesions were created, a baseline blood
sample was drawn and activated clotting time (ACT) was
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Fig. 1 Qualitative, 6-point visual bleeding score system. Score 0, no
bleeding seen from the liver lesion site; Score 0.5, blood observed at
the edge of the liver site though not flowing; Score 1, blood trickles
very slowly from the liver lesion site; Score 2, blood flows slowly
from the liver lesion site; Score 3, blood flow from the liver lesion site
is definite; Score 4, blood flows freely from the liver lesion site in a
steady flow. Scale reproduced with kind permission from Springer
Science?Business Media [12, Fig. 1]
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administered to achieve an ACT of C1.59 baseline
throughout the procedure. After the last lesion was created,
a final ACT measurement was collected.
Surgical procedure: swine liver lesion model
Food was withheld throughout the day and overnight prior
to surgery. General anesthesia was induced with intra-
muscular injection of tiletamine/zolazepam (Telazol;
4.4 mg/kg) and xylazine (2.2 mg/kg) and maintained using
isoflurane. Lactated Ringer’s solution and/or saline was
administered intravenously. Animals were ventilated and
vital signs (temperature, heart rate, respiration rate,
peripheral capillary oxygen saturation, indirect blood
pressure) were monitored throughout the procedure.
Each pig underwent a midline laparotomy using stan-
dard surgical techniques. The liver was exposed and
isolated. Six circular lesions approximately 10 mm diam-
eter 9 7 mm depth were created using a biopsy punch
instrument to each of the left medial, right medial, and left
lateral lobes in each animal. Lesions were spaced 1–2 cm
apart, to prevent cross-contamination of sites. Once cre-
ated, lesion sites took 1–4 s to fill with blood (initial
bleeding scores were either 3 or 4). If any site was not
bleeding adequately, it was scraped with a blade to increase
the flow rate. Where lesion sites were considered unac-
ceptable due to overly severe or inadequate bleeding, a
replacement lesion was created. In cases of severe bleed-
ing, gentle digital pressure, ligation with suture, Gelfoam
T770, FLOSEAL, or thrombin was used to control the
bleeding, and no further data were collected from these
lesions for the study analysis.
The appropriate test article concentration and a saline-
moistened gauze sponge were applied to the designated
liver lesion sites and held by gentle digital pressure for
25–50 s (with a target of 30 s). The gauze was then
removed. Bleeding at each lesion site was scored by the
surgeon at 3, 6, 9, and 12 min (time tolerance of ±1.5 min
for each time point) using the 6-point bleeding score sys-
tem (Fig. 1). The surgeon and the surgical team were
blinded to the concentration of the test article. The clini-
cally acceptable cut-off score was 1.
After completion of surgical procedures and while under
anesthesia, animals were euthanized by intravenous injec-
tion of a sodium pentobarbital-based solution, consistent
with the recommendations of the American Veterinary
Medical Association (AVMA) Panel on Euthanasia [16].
Statistical methods
The sampling unit for this study was the liver lesion site.
Prior to initiation of the study, a sample size analysis was
conducted to determine the number of lesions required to
provide sufficient power to detect differences in mean
bleeding scores between thrombin concentration groups.
Bleeding score data from two previous preliminary stud-
ies (unpublished data, Pfizer) were used to estimate
lesion-to-lesion variability, with standard deviations (SD)
ranging from approximately 1 to 1.25. Using the more
conservative estimate, SD = 1.25, and assuming a 1-sided
2-sample t-test with alpha = 0.05, and 80 % power, a
total of 60 lesions per thrombin concentration group
would lead to a minimum detectable difference in mean
bleeding scores of 0.57.
Statistical analysis of bleeding scores was performed
using an ANOVA model created for each time point (3, 6,
9, and 12 min). The bleeding score was the response
variable and concentration was a fixed effect with three
levels (T250, T375, and T770) and the time 0 bleeding
score was a covariate. If the overall model showed a
1-sided statistical difference at the alpha = 0.05 level,
Tukey p-values (adjusted to account for multiple tests on
the same data) were created to determine pair-wise dif-
ferences between the concentrations. The mean score and
SD were calculated for each concentration (T250, T375,
and T770) at each time point (3, 6, 9, and 12 min). The
percent of scores B1, B0.5, and 0 were summarized for
each concentration.
Results
Clinical assessments indicated all animals to be healthy and
of normal body weight at the initiation of the procedure and
all animals survived the procedure. Baseline coagulation
parameters (prothrombin time, activated partial thrombo-
plastin time, and fibrinogen level) obtained immediately
prior to the onset of the procedure were all within an
acceptable range [17] (Table 1). Three pigs gave baseline
fibrinogen values that were lower than the typical range
(160–390 mg/dL) but were not considered to be abnormal.
Baseline coagulation parameters were not collected for one
animal. However, coagulation parameters after hep-
arinization and bleeding scores were consistent with those
obtained for other animals on the study.
A total of ten pigs (mean weight ± SD, 76.1 ± 6.2 kg)
were used in the study, and bleeding sites were created by
punching circular lesions in their liver while under general
anesthesia. Fifty-eight lesion sites were tested with the
T250 and T375 concentrations and 59 lesion sites were
tested with the T770 concentration, all distributed evenly
across all animals and each of the three liver lobes tested.
The achieved sample size was determined to be statistically
acceptable such that the study could be conducted as
planned.
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For one animal, only four lesion sites were used for
evaluation of T250 and T375 concentrations and only five
lesions sites for T770 (rather than the six specified),
because the pace of bleeding slowed. However, this had no
impact on testing, with the scores elicited from the 13
useable test sites being similar to those elicited from the
remainder of the animals in the study. A total of 31 lesion
sites were deemed unsuitable for evaluation due to inade-
quate or uncontrollable bleeding and never received treat-
ment with the test articles.
At one T770 lesion site, the test article slid off before the
30-s application target was reached. The article and gauze
were re-applied to the site for 30 s and then removed. The
bleeding scores were similar to the remainder of the T770
sites for the animal and were used for evaluation. At one
T250 liver lesion site, approximately 0.5 mL of the test
article was removed during removal of the gauze sponge.
The bleeding scores were slightly higher in comparison to
the remainder of the T250 sites for this animal, but the site
was used for evaluation. One animal suffered a tear in the
most cranial aspect of the left medial liver lobe, which
caused the abdominal cavity to fill with an excessive
volume of blood. However, this did not impact the scores
elicited from the lesion sites on the lobe.
Initial bleeding scores for each test concentration are
shown in Table 2. No significant differences were found
for initial bleeding score (p = 0.7888) or use of additional
scraping (p = 0.6629) between T250, T375, and T770
concentrations. Bleeding scores measured at 3, 6, 9, and
12 min after removal of the gauze sponge are shown in
Table 3 and Fig. 2. After 3 min, 37.9 % of biopsies in the
T250 group achieved a clinically acceptable bleeding score
(B1), compared with 46.6 and 71.2 % in the T375 and
T770 groups, respectively. By 12 min, the percentage of
biopsies achieving a clinically acceptable bleeding score
had increased to 55.2, 69.0, and 88.1 % in the T250, T375,
and T770 groups, respectively.
The bleeding score was also evaluated using repeated
measures linear regression to account for correlation within
each animal. The bleeding score estimates and associated
standard errors from the regression model are shown in
Table 4 and Fig. 3. Using ANOVA with the post hoc
Tukey test for multiple comparisons, the estimated bleed-
ing score for the T250 group was significantly higher than
Table 1 Baseline coagulation
parameters
Animal number Prothrombin time (s) Activated partial thromboplastin time (s) Fibrinogen (mg/dL)
2527 10.7 11.9 217
2529 12.0 11.7 144
2523 11.5 11.7 222
2530 11.0 11.5 180
2528 11.1 11.5 129
2522 11.2 13.7 173
2521 12.0 13.5 131
2524 11.4 12.8 140
2525 11.3 14.0 212
2531a
Reference ranges for normal coagulation activity [17]: Prothrombin time, 10–12 s; Activated partial
thromboplastin time, 10–25 s; Fibrinogen, 160–390 mg/dL
a Baseline coagulation parameters not collected
Table 2 Summary of initial
bleeding scores
Parameter T250, % (n/N) T375, % (n/N) T770, % (n/N)
Initial bleeding score
0 0.0 (0/58) 0.0 (0/58) 0.0 (0/59)
0.5 0.0 (0/58) 0.0 (0/58) 0.0 (0/59)
1 0.0 (0/58) 0.0 (0/58) 0.0 (0/59)
2 0.0 (0/58) 0.0 (0/58) 0.0 (0/59)
3 70.7 (41/58) 72.4 (42/58) 76.3 (45/59)
4 29.3 (17/58) 27.6 (16/58) 23.7 (14/59)
Additional scraping 1.7 (1/58) 0.0 (0/58) 0.0 (0/59)
N total number of lesion sites to which each test article concentration was applied; n number of lesion sites
with each initial bleeding score
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the T770 group at all four time points (p\ 0.0001;
Table 4). The estimated bleeding score for the T375 group
was also significantly higher than the T770 group at all four
time points (p\ 0.0001 at 3 and 6 min; p = 0.0003 at
9 min; p = 0.0011 at 12 min). Estimated bleeding scores
for the T250 group were not significantly different from
bleeding scores for the T375 group at 3, 6, and 9 min
(p = 0.1764; p = 0.0840; and p = 0.1507, respectively).
However, the estimated bleeding score for the T250 group
was significantly higher than the T375 group at 12 min
(p = 0.0448).
Discussion
The aim of this study was to investigate the effect of
increasing concentrations of bovine thrombin in combina-
tion with Gelfoam Powder on resultant hemostasis using a
swine liver lesion model. The study showed that addition of
higher concentrations of thrombin to Gelfoam Powder
yielded improved hemostasis outcomes, as determined by
lower bleeding scores. The hemostatic response to throm-
bin was dose-related: the 770 IU/mL thrombin concentra-
tion was associated with statistically lower bleeding scores
at each time point compared with either the 375 or 250 IU/
mL concentrations.
This is the first in vivo study to directly demonstrate the
positive effect of increasing concentrations of thrombin on
the hemostatic capability of an absorbable gelatin formu-
lation, in this case the Gelfoam Powder. The standardized
Table 3 Summary of bleeding
scores over time by test article
concentration
Scoring interval (min) T250, % (n/N) T375, % (n/N) T770, % (n/N)
Bleeding score of B1 (clinically acceptable)
3 37.9 (22/58) 46.6 (27/58) 71.2 (42/59)
6 43.1 (25/58) 46.6 (27/58) 79.7 (47/59)
9 46.6 (27/58) 62.1 (36/58) 83.1 (49/59)
12 55.2 (32/58) 69.0 (40/58) 88.1 (52/59)
Bleeding score of B0.5
3 27.6 (16/58) 36.2 (21/58) 62.7 (37/59)
6 29.3 (17/58) 31.0 (18/58) 64.4 (38/59)
9 43.1 (25/58) 43.1 (25/58) 69.5 (41/59)
12 43.1 (25/58) 53.4 (31/58) 74.6 (44/59)
Bleeding score of 0
3 24.1 (14/58) 25.9 (15/58) 57.6 (34/59)
6 15.5 (9/58) 22.4 (13/58) 52.5 (31/59)
9 27.6 (16/58) 29.3 (17/58) 55.9 (33/59)
12 31.0 (18/58) 39.7 (23/58) 67.8 (40/59)
N total number of lesion sites to which each test article concentration was applied; n number of lesion sites


















































Fig. 2 Bleeding scores over time by test article concentration.
Bleeding scores measured at 3, 6, 9, and 12 min after removal of
the gauze sponge: a Bleeding scores B0.5; b Bleeding scores B1
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protocol used a biopsy punch instrument to create circular
puncture lesions of consistent diameter but with greater
depth compared with those in other published studies
[1, 12]. Furthermore, the study utilized an ordinal, quali-
tative, 6-point bleeding score system [12] that permitted a
more rigorous statistical analysis compared with those
studies utilizing a ‘bleeding’ versus ‘no bleeding’ assess-
ment as the only outcome measure. As an additional
measure, objectivity of current study data was also
maintained by utilizing a ‘‘blinded’’ assessment protocol,
so that the bleeding scores were rated by investigators who
were blinded to the individual product concentrations of
test articles as applied to various lesions.
The results presented here support a previous study in
which a Gelfoam sponge used in combination with human
thrombin was shown to be more efficacious in controlling
bleeding over multiple time points when compared with
Gelfoam used in combination with saline control [12].
Table 4 Comparison of thrombin concentrations using repeated measures linear regression
Time point (min) Bleeding score estimate (SE) p value*
T250 T375 T770 T250 versus T375 T250 versus T770 T375 versus T770
3 1.8 (0.2) 1.6 (0.2) 0.8 (0.2) 0.1764 \0.0001** \0.0001**
6 1.7 (0.2) 1.4 (0.2) 0.6 (0.1) 0.0840 \0.0001** \0.0001**
9 1.5 (0.2) 1.2 (0.2) 0.6 (0.2) 0.1507 \0.0001** 0.0003**
12 1.4 (0.2) 1.0 (0.2) 0.5 (0.2) 0.0448** \0.0001** 0.0011**
* Tukey p values adjusted for multiple comparisons
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Fig. 3 Bleeding scores over time by concentration. a Adjusted
estimates from the repeated measures linear regression over time by
concentration; b–d Percentage of bleeding scores B1, B0.5, and =0
by concentration over time where T = 0 is the time at which each
lesion was created
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Notably, the study used a lower single concentration of
thrombin (125 IU/mL); and also, the lesions were 3 mm in
depth, compared with 7 mm in the current study. The
findings of this and the present study are complementary,
demonstrating that the addition of thrombin increases the
effectiveness of different preparations of Gelfoam.
The swine liver lesion model is useful for testing
hemostatic interventions for moderate bleeding during
surgical procedures [1, 12]. In the current study, initial
bleeding scores were C3 prior to the application of test
article for all Thrombin–JMI concentrations tested, which
allowed the investigators to be able to note macroscopi-
cally measurable differences when present between the
pre-application and post-application bleeding scores for the
administration sites. Further investigations to confirm how
the results of this study would apply to hemostatic out-
comes for lower degrees of bleeding would be warranted.
The main limitation of the current study was that it
tested a single tissue and lesion type. Future studies could
therefore also seek to confirm the present findings using
other tissues, including those from humans, and with
greater diversity of lesions, akin to those encountered
during human surgical procedures, or using any other
bleeding sites for which the hemostatic products would be
applicable for use in medical practice. An advantage of the
current study is that it used a larger sample size (n = 10
pigs) than other similar studies and, consequently, had
greater statistical power than historical models [1, 12].
Additionally, the choice of standardized model in the
current study was clinically relevant since gelatin and
thrombin products are frequently used, both individually as
well as in combination, in liver surgery.
Another potential limitation of the current study might
be the absence of a Gelfoam-only control study arm. His-
torically, on the other hand, Adams et al. [12] demonstrated
the superiority of Gelfoam sponge with 125 IU/mL human
thrombin compared with Gelfoam sponge alone in a swine
liver lesion model. Future studies that explore comparative
hemostatic outcomes of various combination hemostatic
treatments might similarly consider inclusion of a Gel-
foam-only arm as necessary to further explore specifics of
incremental value.
The current study examined the clinically recommended
concentration of 1000 IU/mL of Thrombin JMI in the
770 IU/mL arm of the study, as the addition of the Gel-
foam powder to the 1000 IU/mL of this thrombin yielded a
final concentration of 770 IU/mL of mixed product in test
article. Lower (100 IU/mL) and higher ranges of the clin-
ically recommended concentrations of Thrombin–JMI (up
to 2000 IU/mL), and even more interestingly concentra-
tions above 2000 IU/mL, might also be explored in future
studies to confirm whether the resultant data would follow
the dose-proportional hemostatic response trend obtained
in the current study. Exploring the concentration ranges for
all thrombins, used either alone or in combination with
other hemostatic agents, on various tissues and surgical
situations might be of particular interest for any future pre-
clinical and clinical studies.
The current study employed bovine thrombin (Throm-
bin–JMI 20,000 IU vials, Pfizer) in combination with
Gelfoam Powder (Pfizer). Bovine thrombin is still used
routinely, while over the past decades, human and recom-
binant (human) thrombin alternatives have also been
developed [3, 5]. Despite the current availability of various
thrombin formulations of different origins for human use,
effects of varying concentrations of thrombin on hemo-
static outcomes in different tissues have rarely been
investigated, and even less in combination with absorbable
gelatin powder. A comparative study investigating the
differences in efficacy by addition of varying concentra-
tions of bovine, human, or recombinant (human) thrombin
to Gelfoam would therefore be warranted. Indeed as tested
in a porcine model, the results of a comparative study
between bovine- and porcine-derived gelatin in combina-
tion with human thrombin demonstrated that the different
sources of gelatin also accounted for variations in hemo-
static efficacy, reportedly due to differences in ultrastruc-
ture [1].
In conclusion, the current study showed that higher
concentrations of thrombin used in combination with
absorbable gelatin powder yields better hemostatic results
in the swine model as demonstrated by the bleeding scores.
As this is the first study ever conducted to look at differ-
ential hemostatic findings between various thrombin con-
centrations, future studies to further investigate the
applications of these findings in other tissues and also
comparisons between thrombins and absorbable gelatins of
different origins are therefore warranted to further refine
surgical approaches to hemostasis.
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